ICDM 2024

Special scientific session 1 Sponsored by Chongkundang The sensible trends: SGLT2I/DPP4I/TZD combination therapy Chair(s): Seak Ki Yun, Jae Hyuk Lee
Thursday 10 October, 08:40~10:10
Room 5

Sponsored by Chongkundang
The combination of TZDs (Thiazolidinediones), DPP-4 inhibitors (Dipeptidyl Peptidase-4 inhibitors), and SGLT2 inhibitors (Sodium-glucose co-Transporter 2 inhibitors) is among the most commonly used treatment strategies for diabetes in South Korea. This scientific session aims to explore the potential patient benefits of combining these classes of medications in pairs. The research presented is expected to contribute significantly to our understanding of the interactions and effects of these medications on diabetic patients, as well as to identify strategies for optimizing therapeutic outcomes. Combining multiple therapies offers the potential to balance the strengths and weaknesses of each drug, thereby enhancing HbA1c control and improving diabetes management from various perspectives.

SS1-1 In-Kyung JeongKyung Hee University, Korea: Enhanced and complementary benefits of SGLT2I and TZD combination

SS1-2 Jae-Han JeonKyungpook National University, Korea: The secular trend combination is symbiotic benefits: SGLT2I+DPP4i

SS1-3 Young Sang LyuChosun University, Korea: Consistently necessary synergistic benefits: TZD and DPP4i

Special scientific session 2 Sponsored by BI-LLY Jardiance, the importance of early intervention to prevent cardiorenal complications Chair(s): Suk Kyeong Kim, Dong-Hyeok Cho
Thursday 10 October, 13:40~15:10
Room 5

Sponsored by BI-LLY
The clinical significance of SGLT2 inhibitors in diabetes treatment is well established, with their role in managing related complications continuously expanding. This session will delve into the role of SGLT2 inhibitors in reducing the long-term risk of cardiorenal complications, beyond their primary function of glycemic control. Following this, the discussion will focus on identifying optimal treatment strategies to prevent or slow the progression of these complications.

SS2-1 Soo LimSeoul National University, Korea: The cardiovascular-kidney-metabolic benefit of SGLT2 inhibitor

SS2-2 Tong Wei YewNational University Hospital, Singapore: Why earlier use of Empagliflozin is crucial in T2D management

SS2-3 Bobby ChackoJohn Hunter Hospital, Australia: Seizing opportunities to improve DKD outcomes

Special scientific session 3 Sponsored by Bayer Finerenone: the novel treatment in CKD with T2D targeting inflammation and fibrosis Chair(s): Sung Woo Ha, Young Jung Cho
Thursday 10 October, 15:20~16:50
Room 3

Sponsored by Bayer
Managing CKD complications is crucial for improving patient outcomes. This discussion will cover Finerenone's impact on CKD in type 2 diabetes, drawing from clinical experiences in western countries, Japan, and Korea. It will provide insights into diverse patient populations and the clinical outcomes of CKD treatment with Finerenone across various regions.

SS3-1 Jiten VoraUniversity of Liverpool, UK: Finerenone for the spectrum for the patients with T2D and CKD: improving CV and kidney outcomes

SS3-2 Masayuki YamanouchiToranomon Hospital, Japan: Inflammation and fibrosis as therapeutic targets in CKD with type 2 diabetes

SS3-3 Minyoung LeeYonsei University, Korea: Outcomes for Korean patients with finerenone

Special scientific session 4 Sponsored by AstraZeneca Many faces of SGLT2 inhibitor Chair(s): Kyu Jeung Ahn, Yong-ho Lee
Thursday 10 October, 15:20~16:50
Room 4

Sponsored by AstraZeneca
This session aims to highlight the various clinical effects of SGLT2 inhibitors. In addition to metabolic effects, SGLT2 inhibitors have been shown to have benefits for various diseases and pathological conditions including AF, hyperkalemia, gout, and cognitive function. In addition, multiple benefits of early implementation of SGLT2 inhibitors will be addressed.

SS4-1 Jae Hyun BaeSeoul National University, Korea: Nonmetabolic effects of SGLT2 inhibitors

SS4-2 Roger ChenSt Vincent’s Hospital, Australia: Cognitive impairment in type 2 diabetes

SS4-3 Jun Sung MoonYeungnam University, Korea: Early intensive treatment with SGLT2 inhibitor

Special scientific session 5 Sponsored by Handok Taking CGM to the next level Chair(s): Young Il Kim, Ji Hee Yu
Thursday 10 October, 15:20~16:50
Room 5

Sponsored by Handok
This session explores cutting-edge evidence in Continuous Glucose Monitoring (CGM) technology. We will examine differences in various CGM metrics, including Time In Range (TIR), Time In Tight Range (TITR), and Glucose Risk Index (GRI); real-time CGM-guided glucose management in hospital and ICU settings, with shared experiences and suggestions; and CGM use during pregnancy. Through these topics, we'll delve into the latest developments, applications, and potential of CGM technology in various clinical contexts.

SS5-1 Ji Yoon KimSungkyunkwan University, Korea: Differences in CGM metrics: TIR, TITR, and GRI

SS5-2 Ilias SpanakisUniversity of Maryland, USA: Utilizing continuous glucose monitoring devices in the hospital setting

SS5-3 Sun-Joon MoonSungkyunkwan University, Korea: CGM use during pregnancy

Special scientific session 6 Sponsored by Dong-A ST New horizons in diabetes care: incretin and next generation drugs Chair(s): Yu-Bae Ahn, Sunghwan Suh
Thursday 10 October, 17:00~18:30
Grand hall 4+5

Sponsored by Dong-A ST
Exploring advances in diabetes care through incretin-based therapies, this session highlights key insights on treatment innovation, the clinical implications of evogliptin trials, and the differentiated metabolic effects of the novel GLP1R/GCGR dual agonist, DA-1726. These discussions will provide a forward-looking perspective on the evolving landscape of diabetes management and offer evidence-based approaches to improving patient outcomes in the next generation of treatments.

SS6-1 Eun Young LeeThe Catholic University of Korea, Korea: Innovation in diabetes treatment through the incretin pathway

SS6-2 Bien J. MatawaranUniversity of Santo Tomas, Philippines: Evogliptin in focus: revolutionizing diabetes care through clinical trials

SS6-3 Yuna ChaeDong-A ST Research Headquarters, Korea: Differentiated metabolic effects of DA-1726, a new GLP1R/GCGR dual agonist

Special scientific session 7 Sponsored by LG Chem National trends and insights into combination therapy with oral antidiabetic agents across Asian countries Chair(s): Tae Keun Oh, Soon Hee Lee
Friday 11 October, 08:40~10:10
Room 5

Sponsored by LG Chem
In this session, we have invited diabetes experts from three Asian countries-Thailand, the Philippines, and Korea-to discuss current trends in diabetes treatment and share their country-specific insights on the utilization of DPP-4 inhibitor and SGLT-2 inhibitor combination therapy. We will specifically present the latest clinical research on gemigliptin, the first anti-diabetic agent developed in Korea, which is now being used across Asia, including in Thailand and the Philippines. Additionally, we will discuss the clinical outcomes and experiences with the recently launched fixed-dose combination of gemigliptin and dapagliflozin.

SS7-1 Rima T. TanCapitol Medical Center, Philippines: The Philippines' experience and best practices using SGLT-2i and DPP-4i for optimal patient care in diabetes

SS7-2 Pongamorn BunnagRamathibodi Hospital, Thailand: Maximizing the benefits of FDC drugs: lessons learned from Thai physicians on SGLT-2i and DPP-4i combination therapy

SS7-3 So Hun KimInha University, Korea: The latest trends of diabetes management in Korea: a spotlight on gemigliptin and its role in combination therapy

Special scientific session 8 Sponsored by GSK Diabetes and vaccination - why, who, when, and how? Chair(s): Dong Sun Kim, Joon Sup Yeom
Friday 11 October, 08:40~10:10
Grand hall 4+5

Sponsored by GSK
Patients with diabetes are particularly vulnerable to infections due to several factors related to their metabolic condition and its impact on immune function. This session will focus on infectious diseases and prevention strategies for patient with diabetes, with an emphasis on the latest clinical evidence and vaccination guidelines.

SS8-1 Hae Kyung KimYonsei University, Korea: Impact of diabetes mellitus on infection risk: examining the burden of infections in patients with diabetes mellitus

SS8-2 Sunghee ParkSoonchunhyang University, Korea: Role of vaccination; recommendations for adults with diabetes mellitus

SS8-3 Young Kyung YoonKorea University, Korea: Vaccination for the prevention of shingles; new things to know

Special scientific session 9 Sponsored by Daewoong Pharmaceutical Deep dive into SGLT2 inhibitor Chair(s): Chang Beom Lee, Seungjoon Oh
Friday 11 October, 11:10~12:40
Room 5

Sponsored by Daewoong Pharmaceutical
SGLT2 inhibitors have been available in Korea for over a decade, with their use expanding from diabetes treatment to the management of cardiovascular and kidney diseases. This session will explore the pharmacological mechanisms of these inhibitors, review the accumulated evidence, and discuss future prospects. Additionally, we will highlight the latest clinical findings on enavogliflozin, the first SGLT2 inhibitor developed in Korea, focusing on its most recent updates.

SS9-1 Melanie DaviesUniversity of Leicester, UK: Update of SGLT2 inhibitors

SS9-2 Sin Gon KimKorea University, Korea: Where does SGLT2 inhibitor come from and where does it go in diabetes?

SS9-3 Parinya ChamnanSanpasitthiprasong Regional Hospital, Thailand: Novel SGLT2 inhibitor – clinical studies of enavogliflozin

Special scientific session 10 Sponsored by Novo Nordisk The current treatment landscape and optimizing treatment solution with fixed-ratio combination therapy in type 2 diabetes Chair(s): Kyu Chang Won, Jung Min Lee
Friday 11 October, 14:20~15:50
Room 5

Sponsored by Novo Nordisk
In this session, we will discuss the current status of insulin treatment in Korea and the Asia-Pacific region, along with experts' insights on the barriers to and potential solutions for achieving optimal insulin therapy for diabetes patients. Following this, the session will focus on the latest clinical trials, examining the global treatment landscape of GLP-1 receptor agonists, which are gaining recognition as a critical treatment option. To conclude, we will introduce the patient benefits of Fixed-Ratio Combination (FRC) therapy by presenting the results of the DUAL program for IDegLira.

SS10-1 Nam Hoon KimKorea University, Korea: The perceived barriers to initiation of insulin therapy among type 2 diabetes patients

SS10-2 Julie Broe HonoréNovo Nordisk Korea, Korea: Evolution of GLP-1RA for holistic diabetes management

SS10-3 Jun Hwa HongEulji University, Korea: Optimizing treatment solution with fixed-ratio combination therapy in type 2 diabetes

구분		사전등록 (~2024년 9월 2일까지)		현장등록 (2024년 10월 9일 ~ 11일)
구분		KDA회원	비회원	KDA회원	비회원
9~11일 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩280,000	₩350,000	₩370,000	₩450,000
9~11일 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩180,000	₩230,000	₩250,000	₩270,000
One-day 등록	전문의(개원의, 교수, 봉직의, 전임의 포함)	₩170,000	₩210,000	-
One-day 등록	전공의, 간호사, 영양사, 사회복지사, 약사, 연구원, 운동처방사 및 기타 (군의관 및 공중보건의 포함)	₩110,000	₩140,000	-
저녁 식사	전체	₩55,000

Program details

평점안내 (For Korean)